been shown to be true but, as this article will discuss, is far between macrophage LPL and atherosclerosis has come more complex than originally anticipated.
from several recent transplantation studies in which the expression of LPL in macrophages was modulated [14] [15] [16] . Such transplantation approaches were necessary be-3 . Importance of LPL expression in the cause homozygous LPL deficient mice die soon after birth atherosclerotic lesion due to the accumulation of chylomicrons, a particular problem in the lungs where they prevent the contact of Of the cell types present in the atherosclerotic lesion, erythrocytes with the endothelium [17] . Babaev et al. [14] LPL is known to be expressed by both monocyte-derived initially transplanted irradiated female mice with foetal macrophages and smooth muscle cells [3, 4] . The differenliver cells, the predominant site of hematopoiesis in tiation of monocytes to macrophages is accompanied by a mammalian embryogenesis, from mice with LPL2 / 2, substantial increase in LPL mRNA, protein and activity LPL1 / 2 and LPL1 / 1 genotypes whereas Van Eck et al. levels [6] and has also recently been shown to lead to an [15] carried out bone marrow transplantation from increase in the level of apolipoprotein C-II [7] , a known LPL2 / 2 and LPL1 / 1 mice. In both cases, the mice activator of LPL [3] . These macrophages transform into were fed an identical atherogenic diet for several weeks foam cells through the accumulation of lipids [1, 2] .
and their atherosclerotic lesion areas were measured. Detailed immunocytochemical and in situ hybridization Similar reductions, of around 50%, were seen in both experiments have shown that it is the macrophage-derived studies in mice that are deficient for macrophage LPL, foam cells, and not smooth muscle cells, that are the thereby indicating that this source of enzyme directly leads primary source of LPL in the lesion [8] . In addition, the to atherosclerosis in the setting of a pro-atherogenic diet. It expression of LPL mRNA, protein and enzymatic activity is also interesting to note that Van Eck and co-workers [15] have all been found to increase in response to damage observed a 2-fold reduction in apolipoprotein E (apoE) sustained by the arterial wall [9, 10] . Vascular injury has levels in macrophage LPL2 / 2 mice. Macrophage-derived long been known to be a precursor of clinical conditions apoE has been shown to have a preventative effect upon associated with atherosclerosis and is, indeed, how the atherosclerosis by promoting cholesterol efflux from the well-established 'response to injury' hypothesis for cells [18] . That macrophage LPL knockout still has such a atherogenesis was derived [1,2].
significantly protective effect upon atherosclerosis in the The possibility that variations in macrophage LPL pro-atherogenic environment induced by reduction of apoE synthesis and secretion might constitute a hereditary expression provides further indication of the central role component of atherosclerosis was investigated by Renier played by the enzyme in the promotion of atherosclerosis. and colleagues [11] who evaluated LPL levels in macroBoth of the studies identified above [15, 16] were carried phages from inbred mouse strains differing in their suscepout in C57BL / 6 mice, a strain that has previously been tibility to diet-induced atherosclerosis. It was observed that shown to have limitations as a model for human atheromacrophages isolated from mice susceptible to atherosclerosis [19] . When fed a pro-atherogenic diet, these mice sclerosis showed a 2-to 3-fold higher basal LPL mass, develop only relatively mild fatty streak lesions, which are activity and mRNA levels than those from mice resistant to exclusively located in the proximal aorta [19] . However, it, thereby inferring a contributive role for LPL in the C57BL / 6 mice that are homozygous negative for LDL progression of the disease. More recently, Semenkovitch et receptor (LDLR2 / 2) display an enhanced susceptibility al. [12] have shown that although feeding an atherogenic to diet-induced atherosclerosis throughout the length of the diet to heterozygous LPL deficient mice results in aorta [20] . In addition, the extent of atherosclerosis in profound dyslipidaemia, due to an increase in non-HDL these mice can be modulated by altering the duration of the lipoproteins, no differences were seen in atherosclerotic high fat diet used to generate the disease process, thus lesion area when compared to normal mice fed the same providing the framework for studies at different stages of diet. It therefore appears that the decreased presence of lesion formation [20] . Using this improved system, Babaev LPL in the vascular wall might have conferred a protective and co-workers used their same experimental approach, as effect against the highly atherogenic lipoprotein profile previously described [14] , to create macrophage LPL [12] . The LPL mRNA, mass and activity levels have also chimeras [16] . They found that LDLR2 / 2 mice reconstibeen found to be substantially higher in monocyte-derived tuted with LPL2 / 2 macrophages developed significantly macrophages from diabetic patients when compared to less atherosclerosis when challenged with an atherosthose from normal subjects, and such an increase can be clerotic diet for either 8 weeks (early stage atherosclerosis) conferred to normal macrophages by culturing them in or 19 weeks (later stage atherosclerosis) compared to those serum obtained from diabetic patients [13] . Given that mice with LPL1 / 1 or LPL1 / 2 macrophages, as deatherosclerosis is a major complication of diabetes, this termined by en face analysis of pinned-out distal aortae. observation provides further evidence for an association of However, when cross-sectional analysis of the proximal LPL with atherogenesis. aorta, the region most susceptible to atherosclerosis, was The most compelling data concerning the relationship carried out (as used in their earlier study) [14] , similar results to those obtained using the en face procedure were production of LDL, arguably the major contributor to the seen at 8 weeks but no differences between genotypes development of atherosclerotic lesions [1,2]. Frequently, were observed at 19 weeks, a time point when the lesions these LDL molecules are oxidized in the intimal space by are extremely complex in this region. It was therefore free radicals which, along with other modifications, inconcluded that although macrophage LPL expression creases their rate of uptake into macrophages through the undoubtedly promotes foam cell formation and atheroscavenger receptors, and thereby promotes further foam sclerosis in vivo, its impact is limited to the macrophagecell formation [1,2]. rich early lesions as opposed to more complex, advanced
In vitro studies carried out in the last few years have lesions.
also indicated the possibility that the enzymatic action of More recently, Clee et al. [21] have carried out studies LPL may affect other cell types present in the atherosto distinguish between the effects of plasma LPL (i.e.
clerotic lesion, namely endothelial and smooth muscle enzyme bound to the endothelial cells and derived precells. For example, Hennig and co-workers [27] have dominantly from the adipose tissue and muscle) and / or demonstrated that selected fatty acids and LPL-derived vessel wall LPL (i.e. enzyme derived mainly from macroremnants of lipoproteins isolated from hyperphages) on atherosclerosis susceptibility in apoE-deficient triglyceridaemic subjects can activate vascular endothelial mice. They showed that decreased LPL expression from cells and disrupt endothelial integrity. As mentioned both sources (LPL1 / 2 E2 / 2) was associated with a earlier, vascular injury is thought to be a principal cause of reduction in atherosclerotic lesion area compared to the the initial recruitment of macrophages to the arterial wall LPL1 / 1 E2 / 2 mice despite a pro-atherogenic lipid and is, therefore, a probable initiating event in atheroprofile. Thus, the loss of the macrophage-derived LPL sclerosis. In addition, LPL enzyme activity has also been protein in the vessel wall had a dominant effect on limiting shown to lead to the proliferation of vascular smooth atherogenesis because a reduction was seen even in the muscle cells [28] . Such cells are known to secrete extracelpresence of an atherogenic lipid profile caused by low lular matrix proteins that promote the formation of fibrous plasma LPL activity.
plaques, a prominent characteristic of the later stages of Overall, therefore, the use of the modern transgenic atherogenesis [1]. technologies, detailed above, have given greater credence All of the observations presented above illustrate how to several previous in vitro studies (reviewed in Refs.
the catalytic actions of LPL affect the progression of [22, 23] ), and firmly indicate that, within the setting of an atherosclerosis. An additional feature of LPL is its ability atherogenic diet, macrophage LPL expression promotes to act as a pro-atherogenic ligand independent of its foam cell formation. However, the involvement of the catalytic activity, a phenomenon that is discussed below. enzyme in the latter stages of the disease, characterised by complex lesions, needs to be resolved.
In addition to the analysis of the relationship between 5 . LPL acts as an atherogenic ligand elevated LPL expression and atherosclerosis, the precise mechanisms through which the enzyme causes macrophage
The ability of LPL to facilitate cellular uptake of lipid uptake and foam cell formation has also been the lipoproteins independently of its catalytic properties was subject of intense research in the last few years. The initially proposed in 1975 following the observation that findings from these studies form the focus of the next LPL molecules remain associated with chylomicrons after section.
hydrolysis and, therefore, might assist in their hepatic uptake [29] . Interest in this hypothesis was not revived until 1991 when Beisiegel and colleagues showed that LPL 4 . The catalytic action of LPL induces the formation was a ligand for the LDL receptor-related protein (LRP) of atherogenic lipoprotein remnants [30] . Further studies have not only identified other ligands for LPL, but have also demonstrated that the enzyme LPL bound to the luminal surface of the vascular associates with various lipoproteins and promotes their endothelium is responsible for mediating the lipolysis of binding to LRP, HSPG, LDL receptor, VLDL receptor, circulating VLDL and chylomicron particles, thereby leadgp330 and apoE receptor 2 (see Refs. [22, 23, 31 ,32] for ing to both a decrease in their size and enrichment in their reviews). cholesteryl ester content [24] . Studies in vitro have shown
The net result of all the interactions between lipoprothat such remnants are readily taken up by macrophages teins and LPL or cell surface receptors is the retention and [25] . In addition to this, the free fatty acids produced by accumulation of lipoproteins in the arterial subendothelial the action of LPL can be re-esterified by macrophages matrix and their rapid uptake by cells. There are three [26] . The net outcome of these processes is the accumulapotential pathways by which LPL may enhance cellular tion of cholesteryl esters within macrophages and, as a uptake of lipoproteins. The first is receptor mediated consequence, their transformation into foam cells [25, 26] .
uptake of lipoproteins bound to the cell surface via LPL LPL-mediated hydrolysis of VLDL also leads to the [33, 34] . Secondly, LPL may act directly as a ligand for receptors [31] and, finally, the entire HSPG-LPL-lipoproal. [45] have shown that in mouse peritoneal macrophages, 21 tein complex may be internalised by a receptor-indepenCa and LPL can synergistically increase the binding and dent pathway [35, 36] . All of these, along with the uptake uptake of native and oxidized LDL, and the deposition of of potential lipolytic products of LPL, would promote the esterified cholesterol derived from it. Possible reasons for 21 transformation of macrophages into foam cells. Various this synergy include the ability of Ca to increase the other aspects of the involvement of LPL, in a non-enbinding of native and oxidized LDL to LPL and to enhance zymatic capacity, in the atherosclerotic process have also the structural stability of LPL [45, 46] . been investigated in the last few years and are discussed It is well established that heparin competes with HSPG below.
and receptors for the binding of LPL [22, 31] . It therefore LPL has been found to substantially enhance the bindfollows that when heparin is present in the blood, cell ing, uptake and degradation of another modified lipoprosurface LPL-lipoprotein complexes should be reduced tein, glycated LDL, in fibroblasts, endothelial cells and and, as a consequence, there should be less lipoprotein macrophages [37] . Glycation of LDL is a naturally occuraccumulation in macrophages. Indeed, an in vivo study in ring chemical modification of its apolipoprotein B residues rats has shown that heparin treatment prolongs the clearby glucose and is, therefore, more prevalent in diabetic ance of oxidized LDL [47] . This hypothesis was further patients [37] . Given that diabetic patients have macrotested recently using a heparin-mimicking compound, RGphages that express higher levels of LPL [13] and that they 13577, currently under consideration for clinical use in the are more likely to produce glycated LDL, it can be prevention of atherosclerosis. Neuger and co-workers [48] proposed that higher levels of this potentially atherogenic found that, as expected, the compound released LPL into lipoprotein may accumulate in their arteries than those rat blood. In addition, their in vitro work showed that from normal subjects, and may therefore go some way RG-13577 released LPL bound to extracellular matrix towards explaining the increased incidence of atheroscleroproduced by both endothelial cells and the monocytesis in diabetic patients.
derived THP-1 macrophages. The binding of LDL to LPL In addition to mediating the binding of lipoproteins to and its subsequent cellular uptake was also prevented by HSPG on cell surfaces, LPL can also perform the same this drug, thereby indicating that targeting of the bridging function with extracellular vascular proteoglycans [22] . In action of LPL could represent a potential strategy for an atherosclerotic lesions, two predominant proteoglycans are anti-atherogenic treatment. versican, present primarily in areas rich in smooth muscle All of the evidence cited above illustrates how LPL acts cells, and biglycan, which is abundant in the extracellular as a molecular bridge due to its ability to bind simulmatrix adjacent to the sites of macrophage infiltration [38] .
taneously to lipoproteins and proteoglycans / receptors via Olin et al. [39] have recently demonstrated that the binding separate domains. The proposed bridging function of LPL of both oxidized and native LDL to versican and biglycan has been supported by numerous tissue culture studies (see is promoted by the presence of LPL. Similarly, glycosRefs. cited above and [22, 23] ) and has also been confirmed aminoglycan filaments extending from collagen fibres in in vivo [49] . A further variation on the bridging theme the subendothelial matrix have been found to accumulate involves cells rather than lipoproteins as LPL has been LDL [40] . Modelling this environment using decorinshown to function as a monocyte adhesion protein by coated collagen, Pentikainen and co-workers [41] have forming a 'bridge' between the arterial subendothelial shown that LPL increases the binding of both native and matrix and monocyte surface HSPG [50, 51] . oxidized LDL. Due to the fact that there are large quantities of collagen in the arterial intima and that proteoglycans substantially accumulate during the course of the atherosclerotic process, there is great potential for 6 . Anti-atherogenic nature of LPL LPL to mediate a significant accumulation of LDL and oxidized LDL on these surfaces [41]. These observations As mentioned earlier, a paradox exists with respect to become particularly striking when the recent work of LPL expression and atherosclerosis. As well as being Kaplan and Aviram [42] is considered. They have shown responsible for atherogenic events in the arterial wall, it that macrophage uptake of oxidized LDL bound to macrohas also been shown to play a generalised anti-atherogenic phage-derived extracellular matrix is entirely dependent role, as proven by a variety of experimental evidence. For upon the presence of LPL. Taken together these studies instance, decreased adipose tissue LPL activity has been indicate that LPL is not only responsible for the accumulaimplicated to be responsible, at least in part, for the tion of atherogenic lipoproteins, but is a crucial factor in hypertriglyceridaemia that is associated with insulin resisttheir uptake by macrophages as well.
ance and type II diabetes, which then makes a major Calcium is known to be present in atherosclerotic contribution to the ensuing atherosclerosis in these inlesions and has the ability to enhance the binding of native dividuals [23, 52] . The suppression of LPL expression in and oxidized LDL to the extracellular matrix [43] and these clinical conditions is believed to be mediated by VLDL to the subendothelial matrix [44] . Latterly, Wang et cytokines that are present at high levels, such as interleukin-6 and tumour necrosis factor-a (TNF-a) compound NO-1886, which increases tissue LPL activity, [23, 52] . In addition, studies on patients participating in the protects against atherosclerosis via elevation of HDL levels Regression Growth Evaluation Statin Study (REGRESS) [68] . have identified a strong link between post-heparin LPL Another class of hypolipidaemic agents, the statins, have activity and severity of angina [53] . Of the patients in the recently been tested in several large clinical trials and lowest LPL activity quartile, 47% reported signs of severe found to cause an approximate 30-40% reduction in angina. However, this figure was significantly lower (29%) coronary events [69, 70] . This was also accompanied by a in the highest LPL activity quartile. Furthermore, a recent significant reduction in both the total cholesterol:HDLclinical study in Japan [54] has also shown considerably cholesterol and LDL-cholesterol:HDL-cholesterol ratios lower levels of pre-heparin serum LPL mass in patients [71] . Interestingly, statins have been shown to enhance with coronary atherosclerosis compared to those in healthy LPL activity in adipose tissue and heart as well as individuals. Moreover, several homozygous LPL-deficient decreasing plasma levels of apolipoprotein C-III, an LPL patients have been found to develop relatively advanced inhibitor [72] . Similar effects upon LPL have also been atherosclerosis [55] . Finally, a number of heterozygous exhibited by a third class of drugs, the fibrates, which have LPL genetic variants have been identified that are associagain proven effective in reducing coronary atherosclerosis ated with a pro-atherogenic lipid profile and an increased [73] . The increased hydrolysis of triglycerides in such risk for cardiovascular disease (see Refs. [32, 56] for recent cases may result in the transfer of lipids and apoliporeviews). This includes the Asp9Asn and Asn291Ser proteins to HDL [74] , and thereby facilitate their excretion. mutations that occur at carrier frequencies of up to 5% and are characterised by a reduction in LPL enzymatic activity [32, 56] . Similarly, the T-93G promoter variant, which 7 . Regulation of LPL by factors implicated in reduces LPL promoter activity by inhibiting the binding of atherogenesis the transcription factors Sp1 and Sp3, has been found to be associated among patients with mild elevation in plasma
The regulation of macrophage LPL by factors that have triglyceride levels and ischemic heart disease [57] . Conbeen implicated in atherosclerosis is likely to make a major versely, a serine 447-stop variant, which is characterized contribution to the initiation and the progression of the by increased LPL activity and has a carrier frequency of disease. It is therefore not surprising that this aspect has approximately 20%, is associated with an anti-atherogenic been the subject of intense research in several laboratories, lipid profile and a reduced risk of coronary heart disease including our own [23, [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] . Similarly, the regulation of [32, 56, 58, 59] .
LPL expression in the muscle and the adipose tissue has It is well-established that efficient lipolysis of tribeen investigated in the light of the anti-atherogenic glyceride-rich lipoproteins in heart, skeletal muscle and potential of LPL produced by these tissues [4, 91, 92] . adipose tissue generally drives the circulating lipoprotein With respect to macrophage LPL, an excellent correlaprofile in a non-atherogenic direction [60] [61] [62] . Thus, in tion has been found in several cases between the role of contrast to macrophage LPL, the endothelium-bound enthe regulating factor in atherogenesis and its action on LPL zyme derived from the parenchymal cells of adipose tissue expression. For example, glucose, hydrogen peroxide and muscle plays an antiatherogenic role. Indeed, Clee et (source of oxidant stress / reactive oxygen intermediates), al. [21] have recently shown that transgenic mice with many free fatty acids (e.g. linoleic acid, palmitic acid, increased plasma LPL but with no changes in the expresstearic acid), homocysteine, platelet-derived growth factor sion of the enzyme in macrophages, and thus the vessel and macrophage colony stimulating factor (M-CSF) all wall, have reduced atherogenesis. Overexpression of LPL increase macrophage LPL expression [23, [75] [76] [77] [78] [79] [80] [81] . The prois highly effective in normalizing the atherosclerotic atherogenic role of all these factors is well documented. lipoprotein profiles of both apoE-deficient and LDL reFor example, peripheral factors dysregulated in diabetes, ceptor-deficient mice and protects wild-type mice against including glucose and free fatty acids, are known to diet-induced hyperlipidaemia [21, [60] [61] [62] . Of particular contribute to the high incidence of atherosclerosis in importance are the levels of HDL, which functions as a diabetic patients [13, 75, 76, 78] . Similarly, hyperremoval vehicle for cholesterol, transporting it away from homocysteinemia represents an independent risk factor for areas of production to the liver for excretion into the bile atherosclerosis [79] . Reactive oxygen intermediates are (reverse cholesterol transport) [63] . In addition, HDL has also present at high levels in the atherosclerotic lesion and been shown to prevent the oxidation of LDL by metal ions have been implicated in the oxidation of LDL and the [64] . Furthermore, genetic syndromes characterised by production of several other pro-atherogenic factors [77] . high HDL levels are usually associated with decreased M-CSF has also been found to be present in the lesion and atherosclerosis [65] . Post-heparin plasma LPL activity has mice lacking the corresponding gene are less susceptible to also been linked directly to HDL levels in humans [66] atherosclerosis [23, 81] . In contrast, consistent with the with a heterozygous LPL genotype associated with reduced complex aetiology of atherosclerosis, a more complicated HDL-cholesterol levels [67] . Equally, administration of the story emerges for several other factors. For instance, macrophage LPL expression is suppressed by bacterial retinoids) has been shown to suppress LPL activity in lipopolysaccharide, a range of cytokines, prostaglandins, skeletal-and cardiac-muscles but not in adipose tissue and oxidized LDL and metabolites that are known to be [93] . More recently, mice that have been fed diets conproduced during LDL oxidation, including lysophosphataining high cholesterol or oxysterol liver X receptortidylcholine, 7b-hydroxycholesterol and 25-hydroxyselective agonists have been found to exhibit a significant cholesterol [82] [83] [84] [85] [86] [87] [88] [89] [90] . As oxidized LDL, bioactive lipids and increase in LPL expression in the liver and macrophages certain cytokines are considered to be pro-atherogenic, the but not in other tissues (e.g. adipose and muscle) [94] . It is precise significance of their LPL suppressing, antitherefore possible that through more research on the atherogenic action currently remains unclear. However, as regulation of LPL expression, particularly the signal atherosclerosis is initially a protective mechanism [1], it is transduction pathways and the transcription factors that are possible that these factors may limit the transformation of involved in the process, pharmacological agents could be macrophages into foam cells during the early stages of developed that differentially regulate LPL expressed by vascular damage until their actions are over-ridden by adipose tissue / muscle and macrophages. changes in the composition and concentration of LPL Several recent studies have also identified additional, activating agents in the local milieu of mediators during novel roles for LPL. For example, as discussed previously, the progression of the disease.
LPL has been found to stimulate the proliferation of The expression of LPL in the muscle and the adipose smooth muscle cells [28] , a potentially atherogenic event. tissue is regulated by nutritional status and a plethora of In addition, LPL induces the expression of the TNF-a gene factors, including hormones, growth factors and lipid in macrophages via a pathway that is mediated through cell metabolite products [4, 91, 92] . Again, a good correlation surface proteoglycans and requires protein kinase C [95-exists in several cases between the atherogenic potential of 97]. LPL also reduces the secretion of apoE in macrothe factor and its action on LPL expression. For example, phages and synergizes with IFN-g in the induction of the hypolipidemic fibrates and the antidiabetic macrophage nitric oxide synthetase expression [98, 99] . thiazolidinediones, which display potent triglyceride-lowGiven the importance of TNF-a, apoE and nitric oxide in ering activities and limit atherogenesis, induce the expresatherogenesis, it is essential that more research is carried sion of the LPL gene through peroxisome proliferator out in order to elucidate the relevance of such a novel role activated receptors [91, 92] .
of LPL and the corresponding mechanisms of action.
In conclusion, the exciting findings from research carried out in the last few years have not only emphasized the 8 . Concluding remarks key role of LPL in atherogenesis but clarified the potential contribution of the enzyme expressed by macrophages and The evidence presented in this review clearly indicates a adipose tissue / muscle in the disease. Thus, the enzyme key pro-atherogenic role of macrophage-derived LPL expressed by the adipose tissue and muscle is generally whereas the enzyme expressed by the muscle and the regarded as anti-atherogenic whereas that produced by adipose tissue acts in an anti-atherogenic manner by macrophages is considered to be pro-atherogenic. In improving the circulating lipoprotein profile. Future theraaddition, an excellent correlation has been found on the peutic approaches should therefore seek to decrease macroaction of several factors on LPL gene expression and their phage LPL expression whilst increasing its action in role in atherosclerosis (e.g. glucose and growth factors). adipose tissue and muscle. Gene therapy [61] represents a Future studies should seek to obtain a detailed understandpotential avenue to achieve such specificity and it is ing of the regulation of LPL expression and develop essential that more research on this aspect is urgently strategies that could be used to modulate its action in a carried out. It is, however, interesting to note that studies tissue / cell-specific manner. on the modulation of LPL expression have identified several examples of tissue / cell-specific regulation. For example, LPS directly suppresses LPL gene expression in A cknowledgements macrophages but not adipocytes [82] . In addition, fibrates selectively induce LPL mRNA levels in the liver but not
The work in the authors' laboratory was supported by the adipose tissue whereas thiazolidinediones have no research grants from the British Heart Foundation. effect in the liver but act primarily on the adipose tissue [91, 92] . Such selectivity is likely to extend to other tissues / cell-types because individuals taking such drugs R eferences have reduced atherosclerosis whereas global elevation of LPL expression by these agents would be expected to 
